ACLS Provider: Course

Incorrect. Adenosine is the first-line drug for treating narrow-complex SVT by slowing conduction through the AV node.

Incorrect. Magnesium sulfate is administered to stabilize the myocardium and treat torsades de pointes effectively.

Incorrect. Biphasic defibrillators deliver effective shocks within the range of 120-200 J to treat VF or pulseless VT.

Incorrect. Epinephrine is given as a continuous infusion to maintain adequate heart rate and perfusion when atropine is ineffective.

Incorrect. Maintaining a compression fraction of greater than 80% ensures the majority of resuscitation time is spent on compressions.

Incorrect. Atrial fibrillation is cardioverted starting at 120-200 J in synchronized mode to avoid delivering the shock during ventricular repolarization.

Incorrect. Pausing compressions for more than 10 seconds interrupts perfusion and reduces the chances of ROSC.

Incorrect. Rotating team roles every 2 minutes prevents fatigue, ensuring consistent delivery of high-quality chest compressions.

Incorrect. This rate ensures effective circulation without causing inadequate ventricular filling.

Incorrect. Calcium gluconate stabilizes the cardiac membrane and reduces the risk of life-threatening arrhythmias caused by hyperkalemia.

Incorrect. Rhythm checks are performed every 2 minutes to evaluate for shockable rhythms and assess the need for defibrillation.

Incorrect. Oxygen levels should be monitored and optimized to maintain saturation within the target range of 92-96%.

Incorrect. Pulse checks during CPR should not exceed 10 seconds to minimize interruptions in chest compressions.

Incorrect. Adenosine is administered as a 0.1 mg/kg rapid IV push for pediatric SVT, followed by a saline flush.

Incorrect. Ventricular fibrillation presents as a disorganized rhythm that requires immediate defibrillation.

Incorrect. Synchronized cardioversion is used to terminate unstable SVT by restoring normal electrical activity in the heart.

Incorrect. High-quality CPR is the primary intervention for PEA, followed by epinephrine administration and addressing reversible causes.

Incorrect. Amiodarone is used to stabilize wide-complex tachycardias in stable patients to prevent deterioration into cardiac arrest.

Incorrect. Magnesium sulfate is used to treat torsades de pointes but is not the first-line drug for VF, where epinephrine is prioritized.

Incorrect. Synchronized cardioversion restores organized cardiac activity in unstable atrial flutter.

Incorrect. Magnesium sulfate stabilizes cardiac myocytes and is the drug of choice for treating torsades de pointes.

Incorrect. PEA is not a shockable rhythm; it is managed with high-quality CPR and addressing the underlying reversible causes.

Incorrect. Providing 6-8 breaths per minute prevents hyperventilation and maintains adequate oxygenation during CPR with an advanced airway.

Incorrect. Ventricular fibrillation (VF) is a shockable rhythm and requires immediate defibrillation to restore an organized rhythm.

Incorrect. IV access is preferred for rapid administration; IO is the alternative if IV access is unavailable.

Incorrect. Naloxone is only used in cases of suspected opioid overdose and is not universally administered in cardiac arrest.

Incorrect. Atropine is given at a dose of 0.5 mg every 3-5 minutes during bradycardia, up to a maximum dose of 3 mg.

Incorrect. VF is a shockable rhythm requiring immediate defibrillation to restore organized electrical activity.

Incorrect. IO access provides a reliable alternative for rapid drug delivery during resuscitation when IV access cannot be obtained.

Incorrect. Minimizes interruptions to maintain blood flow to vital organs.

Incorrect. Atropine is the first-line drug for treating symptomatic bradycardia by increasing heart rate through vagal inhibition.

Incorrect. Pediatric defibrillation begins at 2 J/kg and increases to 4 J/kg for subsequent shocks if needed.

Incorrect. PETCO2 >10 mmHg during CPR indicates effective chest compressions generating sufficient circulation.

Incorrect. First-line treatment to block vagal stimulation and increase heart rate.

Incorrect. Biphasic defibrillators deliver effective shocks within the range of 120-200 J, restoring organized electrical activity.

Incorrect. High-quality CPR is the primary treatment for asystole, along with epinephrine and addressing reversible causes.

Incorrect. The correct initial dose of amiodarone for pulseless VT is 300 mg IV/IO, followed by 150 mg for a second dose if needed.

Incorrect. The most reliable method to confirm and monitor placement by measuring exhaled CO?.

Incorrect. Epinephrine is dosed at 0.01 mg/kg IV/IO during pediatric cardiac arrest to improve coronary and cerebral perfusion.

Incorrect. Hypovolemia is a common reversible cause of PEA and should be addressed with rapid fluid resuscitation.

Incorrect. CPR is the primary intervention for PEA, followed by epinephrine and identification of reversible causes.

Incorrect. Epinephrine at 1 mg IV every 3-5 minutes is used to enhance perfusion during cardiac arrest.

Incorrect. Adenosine is used to terminate stable narrow-complex tachycardia by slowing AV node conduction.

Incorrect. Hypothermia is a reversible cause of cardiac arrest and must be corrected to restore spontaneous circulation.

Incorrect. TTM helps reduce neurological injury after ROSC by maintaining a target temperature between 32-36°C.

Incorrect. Dopamine is used when atropine is ineffective, improving heart rate and contractility by stimulating beta receptors.

Incorrect. Pulse checks are performed every 2 minutes during rhythm assessments to evaluate the effectiveness of resuscitation.

Incorrect. Magnesium sulfate stabilizes the myocardium and is the first-line treatment for torsades de pointes.

Incorrect. Asystole is a non-shockable rhythm requiring high-quality CPR and epinephrine administration.

Incorrect. Adenosine is administered as a rapid IV push at an initial dose of 6 mg to terminate stable SVT.

Incorrect. Magnesium sulfate stabilizes the myocardium and is the drug of choice for torsades de pointes.

Incorrect. Targeted temperature management improves neurological outcomes by preventing further brain injury.

Incorrect. Magnesium sulfate is administered to stabilize the myocardium and terminate torsades de pointes.

Incorrect. Minimizing interruptions to less than 10 seconds preserves perfusion and improves resuscitation outcomes.

Incorrect. Delivering 1 breath every 5-6 seconds prevents hypoventilation or hyperventilation.

Incorrect. Maintaining this range prevents hypoxia while minimizing the risks of hyperoxia and oxidative injury.

Incorrect. Compressing 2-2.4 inches ensures effective perfusion during adult CPR while minimizing the risk of injury.

Incorrect. Compressing one-third the depth of the chest ensures adequate perfusion while minimizing the risk of injury.

Incorrect. Adenosine is used to terminate reentrant arrhythmias in narrow-complex SVT by slowing conduction through the AV node.

Incorrect. Adequate oxygenation and ventilation are critical to preventing hypoxia or hyperoxia after ROSC.

Incorrect. Hypovolemia is a reversible cause of PEA and can be treated with rapid fluid resuscitation.

Incorrect. Thrombosis (pulmonary or coronary) is a reversible cause of cardiac arrest and should be addressed immediately.

Incorrect. Switching compressors every 2 minutes reduces rescuer fatigue, ensuring high-quality chest compressions are maintained.

Incorrect. A 30:2 ratio ensures sufficient oxygenation and circulation in adults during CPR without an advanced airway.

Incorrect. Immediate defibrillation is critical for shockable rhythms like ventricular fibrillation and pulseless VT.